CRISPR Therapeutics AG CRSP

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

The Motley Fool · 13h ago

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

The Motley Fool · 2d ago

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Investing.com · 14d ago

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 16d ago

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

GlobeNewswire Inc. · 19d ago

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

GlobeNewswire Inc. · 19d ago

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 37d ago

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

The Motley Fool · 49d ago

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

The Motley Fool · 51d ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

The Motley Fool · 57d ago

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

The Motley Fool · 72d ago

Is This Millionaire-Maker Biotech Stock a Buy Right Now?

The Motley Fool · 77d ago

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering

The Motley Fool · 83d ago

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

The Motley Fool · 83d ago

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

The Motley Fool · 83d ago

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data

Investing.com · 86d ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

Investing.com · 86d ago

CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?

The Motley Fool · 92d ago

2 Billion Reasons to Love CRISPR Therapeutics Right Now

The Motley Fool · 100d ago

This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area

The Motley Fool · 105d ago

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Benzinga · 120d ago

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

The Motley Fool · 121d ago

This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday

The Motley Fool · 134d ago

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

The Motley Fool · 140d ago

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

The Motley Fool · 152d ago